Nefextinib hemifumarate

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameNefextinib hemifumarate
Drug Alias NameMAX-40279-001Max-40279MAX-40279-01MAX-4MAX-5 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsFibroblast growth factor receptors antagonists
TargetsFibroblast growth factor receptorsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMyelodysplastic Syndromes +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMaxiNovel Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMaxinovel Pty LtdMaxiNovel Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesIdiopathic Pulmonary Fibrosis +[5] 
Inactive IndicationsGastroesophageal Junction NeoplasmsNeoplasm MetastasisStomach Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A